|
Title
|
|
|
|
A systematic review of patient-derived tumor organoids generation from malignant effusions
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| This review assesses the possibility of utilizing malignant effusions (MEs) for generating patient-derived tumor organoids (PDTOs). Obtained through minimally invasive procedures MEs broaden the spectrum of organoid sources beyond resection specimens and tissue biopsies. A systematic search yielded 11 articles, detailing the successful generation of 190 ME-PDTOs (122 pleural effusions, 54 malignant ascites). Success rates ranged from 33% to 100%, with an average of 84% and median of 92%. A broad and easily applicable array of techniques can be employed, encompassing diverse collection methods, variable centrifugation speeds, and the inclusion of approaches like RBC lysis buffer or centrifuged ME supernatants supplementation, enhancing the versatility and accessibility of the methodology. ME-PDTOs were found to recapitulate primary tumor characteristics and were primarily used for drug screening applications. Thus, MEs are a reliable source for developing PDTOs, emphasizing the need for further research to maximize their potential, validate usage, and refine culturing processes. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Critical reviews in oncology, hematology / Chemical Rubber Company [Cleveland, Ohio] - Boca Raton, Fla
| |
|
Publication
|
|
|
|
Boca Raton, Fla
:
2024
| |
|
ISSN
|
|
|
|
1040-8428
| |
|
DOI
|
|
|
|
10.1016/J.CRITREVONC.2024.104285
| |
|
Volume/pages
|
|
|
|
195
(2024)
, p. 1-10
| |
|
Article Reference
|
|
|
|
104285
| |
|
ISI
|
|
|
|
001184362300001
| |
|
Pubmed ID
|
|
|
|
38311013
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
|
The author-created version that incorporates referee comments and is the accepted for publication version Available from 12.08.2024
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|